EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Mary-Ellen Taplin iD, Martin Gleave, Neal D Shore, Angela Lopez-Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Paul L Nguyen, Ronaldo Damião, Toshiyuki Kamoto, Ashley Ross, Alberto Briganti, Boris A Hadaschik und 12 weitere

New England Journal of Medicine · 06.08.2026 · 395 (6) · 546-560

DOI: 10.1056/nejmoa2603878 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.08.2026. Verfasst von Mary-Ellen Taplin und 23 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatectomy, Prostatic Neoplasms, Thiohydantoins. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsProstatectomyProstatic NeoplasmsThiohydantoinsNeoadjuvant TherapyAgedHumansMaleMiddle AgedCombined Modality TherapyDouble-Blind MethodKaplan-Meier EstimateLymph Node ExcisionPathologic Complete ResponseFollow-Up StudiesProgression-Free SurvivalPositron-Emission TomographyAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantRadiotherapy, AdjuvantExanthemaIncidence

Substanzen

Androgen AntagonistsapalutamideThiohydantoins

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston.
  • Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
  • START Carolinas, Myrtle Beach, SC.
  • Johnson & Johnson, Los Angeles.
  • Johnson & Johnson, Spring House, PA.
  • Knight Cancer Institute, Oregon Health and Science University, Portland.

ORCID-Profile: Mary-Ellen Taplin

Förderung

  • Johnson & Johnson

Zitieren

APA

Taplin, M. E., Gleave, M., Shore, N. D., Lopez-Gitlitz, A., Kretschmer, A., Efstathiou, E., Nguyen, P. L., Damião, R., Kamoto, T., Ross, A., Briganti, A., Hadaschik, B. A., Heidenreich, A., Juárez Soto, Á., Ye, H., Gotto, G., Rooney, B., Tian, S. K., Wetherhold, L., …, & PROTEUS Investigators (2026). Perioperative Apalutamide in High-Risk Localized Prostate Cancer. New England Journal of Medicine, 395(6), 546-560. https://doi.org/10.1056/nejmoa2603878

Vancouver

Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, et al. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. New England Journal of Medicine. 2026;395(6):546-560. doi:10.1056/nejmoa2603878

BibTeX
@article{Taplin2026,
  author = {Taplin, Mary-Ellen and Gleave, Martin and Shore, Neal D and Lopez-Gitlitz, Angela and Kretschmer, Alexander and Efstathiou, Eleni and Nguyen, Paul L and Damião, Ronaldo and Kamoto, Toshiyuki and Ross, Ashley and Briganti, Alberto and Hadaschik, Boris A and Heidenreich, Axel and Juárez Soto, Álvaro and Ye, Huihui and Gotto, Geoffrey and Rooney, Brendan and Tian, Shaozhou Ken and Wetherhold, Lisa and Miladinovic, Branko and McCarthy, Sharon A and Evans, Christopher P and Kibel, Adam S and PROTEUS Investigators, PROTEUS Investigators},
  title = {Perioperative Apalutamide in High-Risk Localized Prostate Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {6},
  pages = {546--560},
  doi = {10.1056/nejmoa2603878}
}
Kostenlos starten →